A promising new study presented at the American Association for Cancer Research's annual meeting shows that immunotherapy ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

We are navigating political interference, institutional instability, and growing uncertainty across the cancer research ...

The AACR meeting was full of promising data on the vaccine against cervical cancer, a lung cancer drug and the next ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Immunotherapy let some cancer patients with mismatch repair deficient tumors completely avoid surgery, chemo and radiation, a ...

The session follows the American Association for Cancer Research's prior call to action against executive orders that would ...

For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

A new, small cancer study may give hope to patients with solid tumors in the stomach, esophagus or rectum. The standard ...